Journal: Neurotherapeutics

Article Title: Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis

doi: 10.1016/j.neurot.2026.e00831

Figure Lengend Snippet: Enhanced Th17 cell differentiation pathways and elevated JAK2 expression in myasthenia gravis (MG) patients. A Single-cell RNA sequencing (scRNA-seq) was performed on peripheral blood (PB) samples from treatment-naïve MG patients ( n = 2) and matched healthy controls ( n = 3). B Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of upregulated genes of CD4(+) T cells in MG patients. C Key upregulated genes associated with Th17 cell differentiation pathways. D JAK2 expression in peripheral blood mononuclear cells (PBMCs) from immunotherapy-naïve MG patients and matched healthy controls was measured using RT–qPCR (MG patients n = 30, healthy controls n = 24). E, F Correlation between MG-ADL score (E) or MGC score (F) and paired circulating Th17.1 cell frequencies in refractory MG patients (n = 53). Data are presented as mean ± standard error of the mean (SEM). Statistical analysis was conducted using a two-sided Wilcoxon rank-sum test (D) or Pearson Correlation test (E, F). Statistical significance is indicated by ∗∗p < 0.01.

Article Snippet: In brief, the NEBNext Ultra RNA Library Prep Kit (Illumina) was used to generate the sequencing library, the TruSeq PE Cluster Kit v3-cBot-HS (Illumina) was used to perform sample clustering, and the library preparations were sequenced on an Illumina Novaseq platform.

Techniques: Cell Differentiation, Expressing, Single Cell, RNA Sequencing, Quantitative RT-PCR

Journal: Neurotherapeutics

Article Title: Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis

doi: 10.1016/j.neurot.2026.e00831

Figure Lengend Snippet: Tofacitinib suppresses Th17 cell differentiation pathways in MG patients. A Bulk RNA sequencing (RNA-seq) was performed on peripheral blood mononuclear cells (PBMCs) from MG patients at baseline ( n = 6) and week 16 post-tofacitinib treatment ( n = 4). B KEGG pathway enrichment analysis of downregulated genes in PBMCs of MG patients with tofacitinib treatment. C Gene Set Enrichment Analysis (GSEA) showing suppression of Th17 cell differentiation pathways in MG patients. D-F Key Th17 cell differentiation pathways related genes expression, including IL-23 (D), IL-6 (E), and JAK2 (D) in PBMCs from MG patients ( n = 10–17 for each group) at baseline and week 12 post tofacitinib treatment were measured using RT–qPCR. Data are presented as mean ± standard error of the mean (SEM). Statistical analysis was conducted using Student's two-sided unpaired t -test (E) or two-sided Wilcoxon rank-sum test (D, F). Statistical significance is indicated by ∗∗p < 0.01.

Article Snippet: In brief, the NEBNext Ultra RNA Library Prep Kit (Illumina) was used to generate the sequencing library, the TruSeq PE Cluster Kit v3-cBot-HS (Illumina) was used to perform sample clustering, and the library preparations were sequenced on an Illumina Novaseq platform.

Techniques: Cell Differentiation, RNA Sequencing, Expressing, Quantitative RT-PCR